United Therapeutics Corporation UTHR
569.82 USD +7.80 (+1.39%)
Nov 9, 2026, 11:35 AM EST
556.63 Day range 573.00
445.81 52-week range 614.23
- YTD
- +16.95%
- 1 year
- +26.93%
News
benzinga.com HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660 HC Wainwright & Co. analyst Matthew Caufield assumes United Therapeutics (NASDAQ:UTHR) with a Buy rating and announces Price Target of $660.
benzinga.com TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700 TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $675 to $700.- benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $725 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $697 to $725.
benzinga.com Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703 Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.
marketbeat.com What United Therapeutics (UTHR) Said on Its Q3 Earnings Call United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission…
seekingalpha.com United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript- benzinga.com BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768 BTIG analyst Julian Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $728 to $768.
zacks.com United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
zacks.com United Therapeutics (UTHR) Q3 Earnings Miss Estimates United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.- benzinga.com United Therapeutics Amends Agreement With Arena Pharmaceuticals, Pfizer Subsidiary, Eliminating All Royalty Obligations Under Its Exclusive License Agreement Related to Ralinepag for an Upfront Payment of $525M This transaction demonstrates our confidence in the revenue opportunity for oral ralinepag, which has a pending new drug application under review by the FDA for pulmonary arterial hypertension, as…
businesswire.com United Therapeutics Announces Buydown of Ralinepag Royalty SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment…
businesswire.com United Therapeutics Corporation Reports Third Quarter 2026 Financial Results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions Varda says one SpaceX flight could produce drug crystals capable of supporting medicine for millions of patients.
benzinga.com JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695 JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
benzinga.com $100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.23%. Currently, United Therapeutics has a…
benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
benzinga.com United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts…
benzinga.com Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 23.16%. Currently, United Therapeutics has a…- benzinga.com Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725 Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
- benzinga.com The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s…
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED) U.S. stock futures were higher on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Tuesday's lower close.
benzinga.com Liquidia Settles Bitter Fight With United Therapeutics Liquidia (LQDA) stock jumped 40% after settling all lawsuit battles with United Therapeutics for $380.7M. YUTREPIA PAH sales continue.
benzinga.com Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
benzinga.com Liquidia Corporation Stock Is Trending In After-Hours Following United Therapeutics Settlement: What You Should Know Liquidia shares surged 42.48% in after-hours trading after settling all pending litigation with United Therapeutics over YUTREPIA patents.- benzinga.com Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD The settlement follows the September 30, 2026, ruling by the U.S. District Court for the District of Delaware (the Court) that claims 1 and 14 of U.S. Patent No. 11,826,327 (the ’327 patent) are…
- benzinga.com Liquidia Enters Into A Global Settlement Agreement With United Therapeutics That Resolves All Pending Litigation Between The Companies; Settlement Fully Resolves Six Ongoing Lawsuits Between Liquidia And United Therapeutics; Liquidia To Pay Net $380.70M In Installments In 2026 And 2027; Liquidia Will Make A Net Payment To UTHR Of $175M Within 30 Business Days Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced…
- benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $677 to $708.
- benzinga.com Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $566 Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Weight and raises the price target from $515 to $566.
benzinga.com This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.- benzinga.com United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia Shares of United Therapeutics are rising Thursday following a federal court victory in its patent litigation against competitor Liquidia.
benzinga.com Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.- benzinga.com BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.
- benzinga.com Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order instructing the U.S. Food and Drug Administration (FDA) to withdraw approval of Liquidia’s new drug…
benzinga.com Why is Liquidia (LQDA) Stock Trending After Hours? Liquidia Corp. shares gained 0.13% after hours after closing 57.19% lower following an adverse patent ruling.
benzinga.com Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321 Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and announces Price Target of $321.
benzinga.com Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3 Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
benzinga.com United Therapeutics Says FDA Accepts sNDA For Nebulized Tyvaso Inhalation Solution To Treat IPF Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug…- benzinga.com United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening…
- benzinga.com United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027 Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced…
benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.- benzinga.com United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAH The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary…
- benzinga.com JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687 JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $685 to $687.
- benzinga.com B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613 B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and lowers the price target from $620 to $613.
- benzinga.com BETA Completes First FAA eIPP Electric Aircraft Flights, Transporting Manufactured Organs For United Therapeutics The flights carried manufactured organs, being developed by United TherapeuticsThe flights are also the first in a series of use cases that will touch at least 26 states nationwideBETA Technologies,…
- benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $704 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $701 to $704.
benzinga.com United Therapeutics Expands Immune Therapy Pipeline With Thymmune United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in milestone-based payments.- benzinga.com United Therapeutics Acquired Thymmune Therapeutics For $140M In Cash United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable,…